USA
Nestlé Health Science acquires LivingMatrix personalized medicine platform
LivingMatrix has joined Persona in Nestlé Health Science's Atrium Innovations portfolio.
San Francisco-based LivingMatrix is a personalized functional medicine platform that uses technology-based data and algorithms to leverage healthcare providers.
The platform was designed by clinicians to help practitioners work with patients to effectively create personalized care plans and track patient health outcomes.
“The addition of LivingMatrix will allow us to take the next steps in leading the future of personalized health management. Our goal is to further scale our personalization platform through integrating LivingMatrix with our existing PureGenomics platform and future healthcare provider patient management systems providing the most comprehensive solution in the industry,” said Kyle Bliffert, president of Atrium Innovations.
For more on this story, please click HERE.
Europe
Start-up creates personalized probiotic yoghurt machine
YOGUT ME, a Swedish startup, is working on a kitchen counter machine that makes personalized probiotic and prebiotic filled yogurts.
Biotech entrepreneur Aline de Santa Izabel is working towards making the product available for just $250 and the supplement pods for $2 each in order to ensure the product is competitive with ready-made yogurts.
Looking to the future, de Santa Izabel told our European edition that the machine will allow the ability to create different microbiome modulating pod blends for different functions, such as brain and skin health.
To use the machine, the consumer simply needs to put their choice of milk and the pod into the machine, use the linked app to tell the machine their preferences, and leave it for 10-12 hours to create their bespoke freshly made yogurt.
De Santa Izabel is also looking for more partners across Europe to help her with her venture as she can see huge potential in many countries, especially the UK.
For more on this, please click HERE.
Asia
Gencor’s PEA ingredient gains Australian TGA approval
Australia’s Therapeutic Goods Administration (TGA) has approved Gencor’s palmitoylethanolamide (PEA) for use as an active ingredient in listed medicines.
The ingredient was added to the Australian Register of Therapeutic Substances and can claim health benefits in the area of joint care and alleviating bodily pains. Under TGA rules, Gencor will enjoy a two-year exclusivity in Australia for selling of the ingredient, until Dec 2021.
The ingredient is commercially available under the tradenames Levagen and Levagen+.
“The approval adds a higher level of validation and reputation in the APAC market,” said Gencor’s R.V. Venkatesh.
“Now that we have the TGA approval, that will help us form the basic document for the different markets. We are working on tailoring our dossier for each country to suit the requirement of that country.”
PEA is an endogenous endocannabinoid receptor agonist. It is commonly isolated from soybeans, peanuts, and egg yolks.
For more on this, please click HERE.
